학술논문
Safety profile of afatinib in first-line therapy of patients with metastatic EGFR mutation-positive (M+) non-small cell lung cancer (NSCLC): Comparative analysis of Asian and non-Asian patients from two randomized trials: ID 242
Document Type
Academic Journal
Author
Source
Oncology Research and Treatment. Feb 01, 2014 37 Supp 1:90-90
Subject
Language
English
ISSN
2296-5270